The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Williams Timothy since 2019.
This trader's CIK number is 1748392.
At the time of last reporting, Williams Timothy was the SVP & General Counsel of Vanda Pharmaceuticals Inc.. (stock ticker symbol VNDA).
Also see all insider trading activities at Vanda Pharmaceuticals Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | VNDA | 0 | $0 | 17,088 | $73,320 | 0 | $0 |
| 2023 | VNDA | 0 | $0 | 31,338 | $200,339 | 0 | $0 |
| 2022 | VNDA | 0 | $0 | 20,360 | $219,387 | 0 | $0 |
| 2021 | VNDA | 0 | $0 | 28,845 | $522,883 | 0 | $0 |
| 2020 | VNDA | 0 | $0 | 8,069 | $88,965 | 0 | $0 |
| 2019 | VNDA | 0 | $0 | 2,575 | $37,829 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-03-04 | VNDA | Sale | 8,147 | 4.41 | 35,920 |
| 2024-03-05 | VNDA | Sale | 8,941 | 4.18 | 37,400 |
| 2023-06-13 | VNDA | Sale | 14,600 | 6.56 | 95,761 |
| 2023-03-02 | VNDA | Sale | 8,437 | 6.25 | 52,689 |
| 2023-03-03 | VNDA | Sale | 8,301 | 6.25 | 51,889 |
| 2022-08-15 | VNDA | Sale | 8,300 | 10.31 | 85,606 |
| 2022-03-02 | VNDA | Sale | 12,060 | 11.09 | 133,781 |
| 2021-08-16 | VNDA | Sale | 3,715 | 16.15 | 59,989 |
| 2021-03-05 | VNDA | Sale | 5,600 | 17.86 | 100,043 |
| 2021-03-01 | VNDA | Sale | 11,856 | 18.60 | 220,545 |
| 2021-03-02 | VNDA | Sale | 7,674 | 18.54 | 142,306 |
| 2020-08-14 | VNDA | Sale | 3,684 | 11.81 | 43,526 |
| 2020-03-02 | VNDA | Sale | 3,148 | 10.30 | 32,436 |
| 2020-03-03 | VNDA | Sale | 1,237 | 10.51 | 13,003 |
| 2019-08-14 | VNDA | Sale | 2,575 | 14.69 | 37,829 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Williams Timothy (SVP & General Counsel of Vanda Pharmaceuticals Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.